H.C. Wainwright raised the firm’s price target on Omeros (OMER) to $20 from $9 and keeps a Buy rating on the shares after the company announced an asset purchase and license agreement with Novo Nordisk (NVO) for zaltenibart. Omeros will receive an upfront cash payment of $240M with potential for up to $510M in one-time development and approval milestone payments and up to $1.3B in one-time sales-based milestone payments, as well as tiered royalties on annual net sales of the products, the analyst tells investors in a research note. H.C. Wainwright cites the non-dilutive cash Omeros will receive and revised risk assumptions for zaltenibart for the target increase.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Unusually active option classes on open October 15th
- Omeros Signs Major Deal with Novo Nordisk
- Omeros up 124% at $9.20 after entering license agreement for zaltenibert
- Novo Nordisk, Omeros enter asset purchase, license agreement for zaltenibert
- Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH